Increasing existing treatment coverage and the quality of care available should not be described by mere words, rhetoric and grand announcements but by firm commitments from both the public and private sector.
Supporting healthcare innovation helps ensure that there is motivation and incentive into the treatment of less common ailments such as rare diseases. People with these diseases should not be left behind.
We need to discuss how we can move forward, address concerns related to intellectual property protections, and support the government’s agenda of ongoing national healthcare reform.
The National Surveillance on Antibiotic Resistance has indicated that we have almost every variety of antibiotic resistance thus far documented including some which have not yet made an appearance in other parts of the world.